What is claimed is:

1. An antibody-drug conjugate (ADC) comprising an ~~anti-STEAP2 antibody or antigen-binding fragment thereof and a cytotoxic agent, wherein the antibody or antigen-binding fragment and the cytotoxic agent are covalently attached via a linker.~~

~~2. An isolated~~ antibody or antigen-binding fragment thereof that specifically binds to human six-transmembrane epithelial antigen of prostate 2 (STEAP2~~) expressing cells with an EC50 of less than about 50 nM as measured by an in vitro FACS binding assay as described herein.~~

~~3. The isolated~~), and a cytotoxic agent, wherein the antibody or antigen-binding fragment thereof ~~of claim 2 that is internalized by human STEAP2-expressing cells.~~

~~4. The isolated antibody of claim 3, wherein the antibody is fully human.~~

~~5. The antibody or antigen-binding fragment of any one of claims 2-4,~~and the cytotoxic agent are covalently attached via a linker, and wherein the antibody or antigen-binding fragment thereof ~~competes for binding to human STEAP2 with a reference antibody comprising an HCVR/LCVR amino acid sequence pair as set forth in Table 1.~~

~~6. The antibody or antigen-binding fragment of claim 5, wherein the reference antibody~~ comprises ~~an HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs:2/10; 18/26; 34/42; 50/58; 66/58; 74/58; 82/58; 90/58; 98/58; 106/114; 122/130; 138/146; 154/162; 170/178; 186/194; 202/210; 218/226; 234/242; 250/258; 266/274; 282/290; 298/306; 314/322; 330/338; 346/354; 362/370; and 378/386 .~~

~~7. The antibody or antigen-binding fragment of any one of claims 2-6, wherein the antibody or antigen-binding fragment thereof binds to the same epitope on human STEAP2 as a reference antibody comprising an HCVR/LCVR amino acid sequence pair as set forth in Table 1.~~

~~8. The antibody or antigen-binding fragment of claim 7, wherein the antibody or antigen-binding fragment thereof binds to the same epitope on human STEAP2 as a reference antibody comprising an HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2/10; 18/26; 34/42; 50/58; 66/58; 74/58; 82/58; 90/58; 98/58;~~

106/114; 122/130; 138/146; 154/162; 170/178; 186/194; 202/210; 218/226; 234/242; 250/258; 266/274; 282/290; 298/306; 314/322; 330/338; 346/354; 362/370; and 378/386.

9. An isolated antibody or antigen-binding fragment thereof that binds human STEAP2, wherein the antibody or antigen-binding fragment comprises: (a) the complementarity determining regions (CDRs) of a heavy chain variable region (HCVR) having an amino acid sequence as set forth in Table 1; and (b) the CDRs of a light chain variable region (LCVR) having an amino acid sequence as set forth in Table 1.

10. The isolated antibody or antigen-binding fragment of claim 9, wherein the antibody or antigen-binding fragment comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair selected from the group consisting of: SEQ ID NOs: 2/10; 18/26; 34/42; 50/58; 66/58; 74/58; 82/58; 90/58; 98/58; 106/114; 122/130; 138/146; 154/162; 170/178; 186/194; 202/210; 218/226; 234/242; 250/258; 266/274; 282/290; 298/306; 314/322; 330/338; 346/354; 362/370; and 378/386.

11. The isolated antibody or antigen-binding fragment of claim 10, wherein the antibody or antigen-binding fragment comprises HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 domains, respectively, selected from the group consisting of: SEQ ID NOs:4-6-8-12-14-16; 20-22-24-28-30-32; 36-38-40-44-46-48; 52-54-56-60-62-64; 68-70-72-60-62-64; 76-78-80-60-62-64; 84-86-88-60-62-64; 92-94-96-60-62-64; 100-102-104-60-62-64; 108-110-112-116-118-120; 124-126-128-132-134-136; 140-142-144-148-150-152; 156-158-160-164-166-168; 172-174-176-180-182-184; 188-190-192-196-198-200; 204-206-208-212-214-216;comprising the amino acid sequences of SEQ ID NOs: 220-222-224-228-230-232; 236-238-240-244-246-248; 252-254-256-260-262-264; 268-270-272-276-278-280; 284-286-288-292-294-296; 300-302-304-308-310-312; 316-318-320-324-326-328; 332-334-336-340-342-344; 348-350-352-356-358-360; 364-366-368-372-374-376; and 380-382-384-388-390-392. , respectively.

12. An isolated 2. The ADC of claim 1, wherein the antibody or antigen-binding fragment thereof that binds human STEAP2, wherein the antibody or antigen-binding fragment comprises: (a) a heavy chain variable region (HCVR) having an comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 18, 34, 50, 66, 74, 82, 90, 98, 106, 122, 138, 154, 170, 186, 202,of SEQ ID NO: 218, 234, 250, 266, 282, 298, 314, 330, 346, 362, and 378; and (b) a light chain variable region (LCVR) having an comprising the amino

acid sequence ~~selected from the group consisting~~ of SEQ ID ~~NOs: 10; 26; 42; 58; 114; 130; 146; 162; 178; 194; 210;~~NO: 226~~, 242; 258; 274; 290; 306; 322; 338; 354; 370; and 386.~~ .

~~13. The isolated antibody or antigen-binding fragment of claim 12, wherein the antibody or antigen-binding fragment comprises a HCVR/LCVR amino acid sequence pair selected from the group consisting of: SEQ ID NOs: 2/10; 18/26; 34/42; 50/58; 66/58; 74/58; 82/58; 90/58; 98/58; 106/114; 122/130; 138/146; 154/162; 170/178; 186/194; 202/210; 218/226; 234/242; 250/258; 266/274; 282/290; 298/306; 314/322; 330/338; 346/354; 362/370; and 378/386.~~

~~14. The ADC of claim 1, wherein the anti-STEAP2 antibody or antigen-binding fragment is the antibody or antigen-binding fragment of any one of claims 2-13.~~

~~15~~3. The ADC of claim 1 or ~~14~~2 that is internalized by human STEAP2-expressing cells.


4. The ADC of any one of claims 1-3, wherein the antibody or antigen-binding fragment thereof is fully human.

5. The ADC of any one of claims 1-4, wherein the cytotoxic agent is:

(a) selected from an auristatin, a maytansinoid, a tubulysin, a tomaymycin ~~derivative~~, or a dolastatin ~~derivative.~~;


~~16. The ADC of claim 1 or 14, wherein the cytotoxic agent is~~ (b) an auristatin selected from MMAE or MMAF, or a maytansinoid selected from DM1 or DM4~~.~~; or

~~17. The ADC of claim 1 or 14, wherein the cytotoxic agent is~~ (c) a maytansinoid having the structure of:



(Formula ~~(~~I)~~ or~~

wherein A is arylene or heteroarylene, or



(Formula ~~(~~II~~).~~)

~~18~~wherein:

A_{3a} is an amino acid, a peptide having 2-20 amino acids, an alkyl, an alkynyl, an alkenyl, a cycloalkyl, an aryl, a heteroaryl, a heterocyclyl, $-CR_5R_6-$, -O-, -C(=O)-, -O-C(=O)-, -C(=O)-O-, -O-C(=O)-O-, $-C(=O)-(CH_x)_{p1}-$, $-C(=O)-O-(CH_x)_{p1}-$, $-(CH_x)_{p1}-C(=O)-$, $-(CH_x)_{p1}-C(=O)-O-$, $-(O-(CH_2)_{p2}-)_{p3}-$, $-((CH_2)_{p2}-O-)_{p3}-$, -C(=S)-, -C(=S)-S-, -C(=S)-NH-, -S-C(=S)-, -S-C(=S)-S-, -S-, -SO-, $-SO_2-$, $-NR_4-$, $-N(R_4)-C(=O)-N(R_8)-$, $-N(R_4)-C(=O)O-$, $-N(R_4)-C(=O)-$, $-C(=O)-N(R_4)-$, $-C(=O)-N(R_4)-C(=O)-$, or $-O-C(=O)-NR_4-$; and


$p1$, $p2$ and $p3$ are each independently 0, or an integer from 1 to 100;

x is 0, 1 or 2;


R_4, R_5, R_6 and R_8 are each independently H, or a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl; and

R_{4a} is a substituted or unsubstituted: alkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl.


6. The ADC of claim ~~17~~5, wherein the maytansinoid is:



~~19~~ ; or




; or



.


7. The ADC of ~~claim 17, wherein the maytansinoid is:~~




.

~~20. The ADC~~any one of ~~claim~~claims 1 ~~or 14~~-4, comprising ~~an anti-STEAP2~~the antibody or antigen-binding fragment thereof, and:

~~wherein~~ (a)




wherein  is a bond to the antibody or antigen-binding fragment thereof; or



(b)

wherein  is a bond to the ~~anti-STEAP2~~ antibody or antigen-binding fragment thereof~~.~~; or


~~21. The ADC of claim 1 or 14, comprising an anti-STEAP2 antibody or fragment thereof, and~~



(c)

wherein  is a bond to the ~~anti-STEAP2~~ antibody or antigen-binding fragment thereof.


~~22~~8. The ADC of claim ~~1 or 14, comprising an anti-STEAP2 antibody or fragment thereof, and~~




wherein  is a bond to the anti-STEAP2 antibody or fragment thereof.

23. The ADC of any one of claims 20-227, wherein bond contacts the antibody or fragment thereof via a sulfur constituent of a cysteine residue.

249. The ADC of claimany one of claims 1 or 14-4, comprising an anti-STEAP2the antibody or antigen-binding fragment thereof, and



, or



, or

a mixture thereof,

wherein  is a bond to the anti-STEAP2 antibody or antigen-binding fragment thereof.

2510. The ADC of claim 249, wherein the bond contacts the antibody or antigen-binding fragment thereof via a nitrogen constituent of a lysine residue.

2611. The ADC of any one of claims 1 or 14-25-10, wherein the ADC comprises 1 to 4 cytotoxic agents per anti-STEAP2 antibody or antigen-binding fragment thereof.

2712. A pharmaceutical composition comprising the antibody-drug conjugate of any one of claims 1 or 14-26-11, and a pharmaceutically acceptable carrier or diluent.

28. A bispecific antigen-binding molecule comprising a first antigen-binding domain that binds human CD3 and a second antigen-binding domain that binds human STEAP2, wherein the second antigen-binding domain is derived from the13. An antibody or antigen-binding fragment of any one of claims 2-13.

29. A bispecific antigen-binding molecule comprising a first antigen-binding domainthereof that specifically binds human CD3, and a secondsix-transmembrane epithelial antigen binding domain that specifically binds human of prostate 2 (STEAP2.

30. The bispecific antigen-binding molecule of claim 28 or claim 29, wherein the first antigen-binding domain binds human cells)-expressing human CD3 and cynomolgus monkey cells expressing cynomolgus CD3.

31. The bispecific antigen-binding molecule of claim 28 or claim 29, wherein the second antigen-binding domain binds human cells expressing human STEAP2.

32. The bispecific antigen-binding molecule of any one of claims 28-31, wherein each of the first antigen-binding domain and the second antigen-binding domain is fully human.

33. The bispecific antigen-binding molecule of claim 28 or claim 29, wherein the antigen-binding molecule binds both human CD3 and human STEAP2 and induces T cell-mediated cell killing of STEAP2-expressing cells.

34. The bispecific antigen-binding molecule of claim 28 or claim 29 wherein the antigen-binding molecule inhibits tumor growth in immunocompromised mice bearing human prostate cancer xenografts.

35. The bispecific antigen-binding molecule of any one of claims 28-34 that is a bispecific antibody or bispecific antigen-binding fragment thereof.

36. The bispecific antigen-binding molecule of any one of claims 28-35, wherein the second antigen-binding domain that specifically binds human STEAP2 comprises the heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) from a heavy chain variable region (HCVR) selected from the group consisting of SEQ ID NOs: 2, 18, 34, 50, 66, 74, 82, 90, 98, 106, 122, 138, 154, 170, 186, 202, 218, 234, 250, 266, 282, 298, 314, 330, 346, 362, and 378; and the light chaincomprising complementarity determining regions (LCDR1, LCDR2HCDR1, HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 220, 222, and 224, respectively, and LCDR3) from a light chain variable region (LCVR) comprising an amino acid sequence selected from the group consistingcomplementarity determining regions LCDR1, LCDR2, and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 10; 26; 42; 58; 114; 130; 146; 162; 178; 194; 210; 226, 242; 258; 274; 290; 306; 322; 338; 354; 370; and 386.

37. The bispecific antigen-binding molecule of any one of claims 28-35, wherein the second antigen-binding domain that specifically binds human STEAP2 comprises three heavy chain complementarity determining regions (A2-HCDR1, A2-HCDR2 and A2-HCDR3) and three light chain complementarity determining regions (A2-LCDR1, A2-LCDR2 and A2-LCDR3), wherein A2-HCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:4, 20, 36, 52, 68, 76, 84, 92, 100, 108, 124, 140, 156, 172, 188, 204, 220, 236, 252, 268, 284, 300, 316, 332, 348, 364, and 380; A2-HCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:6, 22, 38, 54, 70, 78, 86, 94, 102, 110, 126, 142, 158, 174, 190, 206, 222, 238, 254, 270, 286, 302, 318, 334, 350, 366, and 382; A2-HCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:8, 24, 40, 56, 72, 80, 88, 96, 104, 112, 128, 144, 160, 176, 182, 208, 224, 240, 256, 272, 288, 304, 320, 336, 352, 368, and 384; A2-LCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:12, 28, 44, 60, 116, 132, 148, 164, 180, 196, 212, 228, 244, 260, 276, 292, 308, 324, 340, 356, 372, and 388; A2-LCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:14, 30, 46, 62, 118, 134, 150, 166, 182, 198, 214, 230, 246, 262, 278, 294, 310, 326, 342, 358, 374, and 390; and A2-LCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:16, 32, 48, 64, 120, 136, 152, 168, 184, 200, 216, and 232, 248, 264, 280, 296, 312, 328, 344, 360, 376, and 392respectively.

38. 14. The bispecificantibody or antigen-binding moleculefragment thereof of any one of claims 28-35claim 13, wherein the second antigen-binding domain that specifically binds human STEAP2 comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair selected from the group consisting of: SEQ ID NOs: 250/258.

39. The bispecific antigen-binding molecule of any one of claims 28-35, wherein the first antigen-binding domain that specifically binds human CD3 comprises heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) from a heavy chain variable region (HCVR) comprising an amino acid sequence as set forth in Table 9, Table 11, or Table 15 and light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) from a light chain variable region (LCVR) comprising an amino acid sequence as set forth in Table 1, Table 9, Table 12, or Table 17.

40. The bispecific antigen-binding molecule of any one of claims 28-35, wherein the first antigen-binding domain that specifically binds human CD3 comprises heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) from a heavy chain variable region (HCVR) selected from the group consisting of SEQ ID NOs: 1730, 1762, and 1866, and light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) from a light chain variable region (LCVR) comprising an comprises the amino acid sequence of SEQ ID NO: 258.

41. The bispecific antigen-binding molecule of any one of claims 28-35, wherein the first antigen-binding domain that specifically binds human CD3 comprises three heavy chain complementarity determining regions (A1-HCDR1, A1-HCDR2 and A1-HCDR3) and three light chain complementarity determining regions (A1-LCDR1, A1-LCDR2 and A1-LCDR3),

wherein A1-HCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1732, 1764, and 1868; A1-HCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1734, 1766, and 1870; A1-HCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1736, 1768, and 1872; A1-LCDR1 comprises an 218, and the LCVR comprises the amino acid sequence of SEQ ID NO: 260; A1-LCDR2 comprises an amino acid sequence of SEQ ID NO: 262; and A1-LCDR3 comprises an amino acid sequence of SEQ ID NO: 264226.

42. The bispecific antigen-binding molecule of any one of claims 28-35, wherein the first antigen-binding domain that specifically binds human CD3 comprises the heavy and

light chain CDRs of a HCVR/LCVR amino acid sequence pair selected from the group consisting of: SEQ ID NOs: 1730/258, 1762/258, and 1866/258.

43. The bispecific antigen-binding molecule of any one of claims 28-35, wherein the first antigen-binding domain that specifically binds human CD3 comprises three heavy chain complementarity determining regions (A1-HCDR1, A1-HCDR2 and A1-HCDR3) and three light chain complementarity determining regions (A1-LCDR1, A1-LCDR2 and A1-LCDR3), and wherein the second antigen-binding domain that specifically binds human STEAP2 comprises three heavy chain complementarity determining regions (A2-HCDR1, A2-HCDR2 and A2-HCDR3) and three light chain complementarity determining regions (A2-LCDR1, A2-LCDR2 and A2-LCDR3);

wherein A1-HCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1732, 1764, and 1868; A1-HCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1734, 1766, and 1870; A1-HCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1736, 1768, and 1872; A1-LCDR1 comprises an amino acid sequence of SEQ ID NO: 260; A1-LCDR2 comprises an amino acid sequence of SEQ ID NO: 262; and A1-LCDR3 comprises an amino acid sequence of SEQ ID NO: 264; and

wherein A2-HCDR1 comprises an amino acid sequence of SEQ ID NO: 252; A2-HCDR2 comprises an amino acid sequence of SEQ ID NO: 254; A2-HCDR3 comprises an amino acid sequence of SEQ ID NO: 256; A2-LCDR1 comprises an amino acid sequence of SEQ ID NO: 260; A2-LCDR2 comprises an amino acid sequence of SEQ ID NO: 262; and A2-LCDR3 comprises an amino acid sequence of SEQ ID NO: 264.

44. The bispecific antigen-binding molecule of any one of claims 28-35, wherein the first antigen-binding domain that specifically binds human CD3 comprises a heavy chain comprising variable domain framework regions having an amino acid sequence selected from FR1 (SEQ ID NO: 1903), FR2 (SEQ ID NO: 1904), FR3 (SEQ ID NO: 1905), and FR4 (SEQ ID NO: 1906).

45. The bispecific antigen-binding molecule of any one of claims 28-35, wherein the first antigen-binding domain that specifically binds human CD3 comprises a HCVR comprising HCDR1-HCDR2-HCDR3 having the amino acid sequences of SEQ ID NOs: 1907-1908-19091.

46. The bispecific antigen-binding molecule of any one of claims 28-35, wherein the second antigen-binding domain competes for binding to human STEAP2 with a reference antigen-binding protein comprising three heavy chain complementarity determining regions (A2-HCDR1, A2-HCDR2 and A2-HCDR3) and three light chain complementarity determining regions (A2-LCDR1, A2-LCDR2 and A2-LCDR3), wherein A2-HCDR1 comprises an amino acid sequence of SEQ ID NO: 252; A2-HCDR2 comprises an amino acid sequence of SEQ ID NO: 254; A2-HCDR3 comprises an amino acid sequence of SEQ ID NO: 256; A2-LCDR1 comprises an amino acid sequence of SEQ ID NO: 260; A2-LCDR2 comprises an amino acid sequence of SEQ ID NO: 262; and A2-LCDR3 comprises an amino acid sequence of SEQ ID NO: 264.

47. The bispecific antigen-binding molecule of any one of claims 28-35, wherein the second antigen-binding domain competes for binding to human STEAP2 with a reference antigen-binding protein comprising a heavy chain variable region (HCVR) comprising an amino acid sequence of SEQ ID NO: 250, and a light chain variable region (LCVR) comprising an amino acid sequence of SEQ ID NO: 258.

48. The bispecific antigen-binding molecule of any one of claims 28-35, wherein the first antigen-binding domain competes for binding to human CD3 with a reference antigen-binding protein comprising three heavy chain complementarity determining regions (A1-HCDR1, A1-HCDR2 and A1-HCDR3) and three light chain complementarity determining regions (A1-LCDR1, A1-LCDR2 and A1-LCDR3), wherein A1-HCDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1732, 1764, and 1868; A1-HCDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1734, 1766, and 1870; A1-HCDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 1736, 1768, and 1872; A1-LCDR1 comprises an amino acid sequence of SEQ ID NO: 260; A1-LCDR2 comprises an amino acid sequence of SEQ ID NO: 262; and A1-LCDR3 comprises an amino acid sequence of SEQ ID NO: 264.

49. The bispecific antigen-binding molecule of any one of claims 28-35, wherein the first antigen-binding domain competes for binding to human CD3 with a reference antigen-binding protein comprising a heavy chain variable region (HCVR) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1730, 1762, and 1866, and a light chain variable region (LCVR) comprising an amino acid sequence of SEQ ID NO:258.

50. The bispecific antigen-binding molecule of any one of claims 28-35, wherein

~~the first antigen-binding domain competes for binding to human CD3 with a reference antigen-binding protein comprising a heavy chain variable region (HCVR) comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1730, 1762, and 1866, and a light chain variable region (LCVR) comprising an amino acid sequence of SEQ ID NO:258; and wherein the second antigen-binding domain competes for binding to human STEAP2 with a reference antigen-binding protein comprising a heavy chain variable region (HCVR) comprising an amino acid sequence of SEQ ID NO:250, and a light chain variable region (LCVR) comprising an amino acid of SEQ ID NO: 258.~~

~~51~~15. The antibody or antigen-binding fragment thereof of claim 13 or 14 that is internalized by human STEAP2-expressing cells.

16. The antibody or antigen-binding fragment thereof of claim 13 or 14, wherein the antibody or antigen-binding fragment thereof is fully human.

17. The antibody or antigen-binding fragment thereof of claim 13 or 14 that is bispecific.

18. A nucleic acid molecule comprising a nucleotide sequence encoding an antibody or antigen-binding fragment of claim 13 or 14, or a pair of nucleic acid molecules comprising nucleotide sequences, respectively, encoding the HCVR of the antibody or antigen-binding fragment, and the LCVR of the antibody or antigen-binding fragment of claim 13 or 14.

19. An expression vector comprising the nucleic acid molecule of claim 18, or a pair of expression vectors comprising, respectively, the pair of nucleic acid molecules of claim 18.

20. An isolated host cell comprising the antibody or antigen-binding fragment of claim 3 or 14, the nucleic acid molecule or pair of nucleic acid molecules of claim 18, or the expression vector or pair of expression vectors of claim 19.

21. A method of producing an anti-STEAP2 antibody or antigen-binding fragment thereof, comprising culturing the host cell of claim 20 under conditions permitting production of the antibody or antigen-binding fragment, and recovering the antibody or antigen-binding fragment so produced.

22. The method of claim 21, wherein the host cell is a Chinese hamster ovary cell.

23. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of any one of claims ~~2-13 or the bispecific antigen-binding molecule of any one of claims 28-50~~13-17, and a pharmaceutically acceptable carrier or diluent.

~~52. A method for treating a cancer in a subject,~~ 24. Use of the ~~method comprising administering to the subject~~ADC of any one of claims 1-11, or the pharmaceutical composition of claim ~~51~~12, in the manufacture of a medicament for treating a STEAP2-expressing cancer in a subject.

~~53~~25. The ~~method~~use of claim ~~52~~24, wherein the STEAP2-expressing cancer is selected from the group consisting of prostate cancer, bladder cancer, cervical cancer, lung cancer, colon cancer, kidney cancer, breast cancer, pancreatic cancer, stomach cancer, uterine cancer, and ovarian ~~cancer.~~ canc9r.

~~54~~26. The ~~method~~use of claim ~~53~~25, wherein the STEAP2-expressing cancer is prostate cancer~~, optionally castrate-resistant prostate cancer.~~.

~~55. Use of the pharmaceutical composition of claim 27 or claim 51 in the treatment of a disease or disorder associated with expression of STEAP2.~~

~~56. The use of claim 55, wherein the disease or disorder is cancer.~~

~~57. A compound comprising the antibody or antigen-binding fragment of any one of claims 2-13 or the bispecific antigen-binding molecule of any one of claims 28-50 for use in medicine.~~

~~58. A compound for use in the treatment of prostate cancer, wherein the compound comprises the antibody or antigen-binding fragment of any one of claims 2-13 or the bispecific antigen-binding molecule of any one of claims 28-50.~~

~~59. Use of the antibody or antigen-binding fragment of any one of claims 2-13 or the bispecific antigen-binding molecule of any one of claims 28-50 for the manufacture of a medicament for use in the treatment of cancer, optionally wherein the cancer is prostate cancer.~~

~~60. A compound comprising the ADC of any one of claims 1 or 14-26 for use in medicine.~~

~~61. A compound for use in the treatment of prostate cancer, wherein the compound comprises the ADC of any one of claims 1 or 14-26.~~

~~62. Use of the ADC of any one of claims 1 or 14-26 for the manufacture of a medicament for use in the treatment of cancer, optionally wherein the cancer is prostate cancer.~~